Detail akcie Ginkgo Bio Rg-A online

Business Summary: Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Ginkgo Bioworks Holdings Inc revenues decreased 15% to $183.2M. Net loss decreased 35% to $439.5M. Revenues reflect Biosecurity segment decrease of 56% to $44M. Lower net loss reflects Not Allocated segment loss decrease of 86% to $54.3M, Cell Engineering segment loss decrease of 60% to $125.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$14.08 to -$8.62.